Veracyte, Inc. (NASDAQ:VCYT) is a leading genomic diagnostics company that develops and commercializes tests designed to improve diagnostic accuracy and patient management in oncology and other critical disease areas. Founded in 2008 and headquartered in South San Francisco, California, Veracyte leverages next-generation sequencing and advanced bioinformatics to deliver minimally invasive tests that help clinicians make more informed decisions. The company operates CLIA-certified laboratories in the United States and Europe, serving a global network of physicians, pathologists and specialty clinics.
The company’s flagship Afirma test for thyroid nodules uses RNA expression analysis to distinguish benign from suspicious samples collected via fine-needle aspiration, reducing unnecessary surgeries. Its Percepta Bronchial Genomic Classifier analyzes airway epithelial cells obtained during bronchoscopy to assess lung cancer risk, while the Envisia Genomic Classifier aids in the diagnosis of idiopathic interstitial pneumonia. These tests address significant unmet needs by providing actionable insights, streamlining clinical pathways and potentially lowering overall healthcare costs.
Veracyte has also established strategic partnerships and licensing agreements to expand its portfolio, including rights to Prosigna, a breast cancer risk assessment assay, and collaborations with pharmaceutical companies to support drug development and companion diagnostic programs. The company’s tests are reimbursed by Medicare and a growing number of private insurers in the United States, with market access efforts underway in Europe and Asia to broaden patient reach.
Under the leadership of President and Chief Executive Officer Dr. Bonnie Anderson since 2015, Veracyte continues to invest in research and development to drive innovation across its diagnostic offerings. The executive team and board comprise seasoned experts in molecular diagnostics, life sciences and healthcare commercialization, all aligned with the company’s mission to transform patient care through precise, genomics-based solutions.
AI Generated. May Contain Errors.
